NF1 and von Hippel-Lindau disease: Additionally, patients with hereditary tumor syndromes (von Hippel–Lindau disease [VHL], Neurofibromatosis Type 1 [NF1], Multiple Endocrine Neoplasia Type 2 [MEN2], Succinate Dehydrogenase mutations [SDHx]) are routinely screened for PPGL, leading to earlier detection in these families, often with smaller tumor sizes [4].